{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0"}]}],"title":"sCR or CR or VGPR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.0"}]}],"title":"PR or SD or PD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0"}]}],"title":"Not Assessed"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"The percentage of participants reported in each disease category by International Myeloma Working Group (IMWG) uniform response criteria for Multiple Myeloma 6 months after autologous Hematopoietic stem cell transplant. Overall Disease Response categories were: \\[stringent Complete Response (sCR)=CR + normal Free Light Chain (FLC) ratio + absence of clonal cells in bone marrow\\], \\[Complete Response (CR)=Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in bone marrow\\], \\[Very Good Partial Response (VGPR)=Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein + urine M-protein level \\<100 mg/24 hour\\], \\[Partial Response (PR)=≥50% reduction of serum M-protein and reduction in 24 hour urine M-protein by ≥90% or to \\<200 mg per 24 hour\\], \\[Stable Disease (SD)=Not meeting criteria for CR, VGPR, PR or progressive disease\\] or \\[Progressive Disease (PD)\\].","groups":[{"description":"Intravenous (IV) busulfan was administered as a single daily 3-hour continuous infusion based on the PK-directed dose recommendation for 4 days beginning on Day -5 followed by a single bortezomib 1.3 mg/m\\^2 dose administered as a 3 to 5-second bolus IV injection on Day -1 prior to HSCT.","id":"OG000","title":"IV Busulfan"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat population included all participants who received the PK-directed IV busulfan followed by autologous HSCT.","reportingStatus":"POSTED","timeFrame":"6 Months","title":"Percentage of Participants With Overall Disease Response at Month 6","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}